Lupin Results

Margin improvement holds key for Lupin with US sales likely to soften

Go ahead for inhaler launch in the US and resolution of plant compliance issues are other triggers

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Lupin Q3 net loss widens to Rs 835 crore, sales drop to Rs 3,716 crore

Consolidated sales of the company stood at Rs 3,716 crore for the quarter under consideration

Lupin posts Q3 loss of Rs 152 crore on litigation over blood pressure drug

Lupin reported a one-time charge of Rs 342 crore in Q3

Lupin fourth quarter profit up 48%, beats estimates

Company reported a net profit of Rs 807 crores for the January-March quarter